Drug Profile
Ondelopran - R-Pharm
Alternative Names: LY-2196044; Odelepan; Odelepran; OpRALatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Developer Eli Lilly and Company; R-Pharm
- Class Drug withdrawal therapies; Pyrans; Pyridines; Small molecules
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alcoholism
Most Recent Events
- 18 Sep 2018 No development reported - Phase-III for Alcoholism in Kazakhstan (PO)
- 18 Sep 2018 No development reported - Phase-III for Alcoholism in Russia (PO)
- 30 Apr 2013 Discontinued - Phase-II for Alcoholism in USA (PO)